New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
11:50 EDTVRTXVertex shares fully valued, says Piper Jaffray
Piper Jaffray believes shares of Vertex are fully valued at current levels after the company reported positive Phase III data. The firm keeps a Neutral rating on the stock with an $87.50 price target.
News For VRTX From The Last 14 Days
Check below for free stories on VRTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
07:24 EDTVRTXVertex management to meet with Deutsche Bank
Subscribe for More Information
September 17, 2014
07:09 EDTVRTXVertex price target raised to $127 from $103 at Deutsche Bank
Subscribe for More Information
September 10, 2014
09:27 EDTVRTXVertex shares likely to advance further, says RBC Capital
Subscribe for More Information
September 9, 2014
11:47 EDTVRTXStocks with call strike movement; FSLR VRTX
First Solar (FSLR) March 80 call option implied volatility increased 2% to 42, Vertex (VRTX) January 105 call option implied volatility increased 6% to 41 according to IVolatility.
September 8, 2014
11:05 EDTVRTXOptions with increasing implied volatility
Options with increasing implied volatility: NPSP GILD VNET AVNR GTAT YHOO RHT VRTX SDRL COV MYL
September 5, 2014
10:05 EDTVRTXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
05:41 EDTVRTXVertex upgraded to Buy from Neutral at Goldman
Goldman Sachs upgraded Vertex Pharmaceuticals to Buy saying it sees a 90% probability of approval for the company's VX-809/Kalydeco combo for cystic fibrosis and a higher likelihood of M&A following the positive Phase 3 data in June. Goldman raised its price target for shares to $131 from $109.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use